Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Allergan Inc patents (2016 archive)


Recent patent applications related to Allergan Inc. Allergan Inc is listed as an Agent/Assignee. Note: Allergan Inc may have other listings under different names/spellings. We're not affiliated with Allergan Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Allergan Inc-related inventors


Non-cytotoxic protein conjugates

The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a targeting moiety (tm), wherein the tm is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a translocation domain, wherein the translocation domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell wherein the targeting moiety is selected from the group consisting of bam, β-endorphin, bradykinin, substance p, dynorphin and/or nociceptin.. ... Allergan Inc

Cross linked silk-hyaluronic acid composition

Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.. ... Allergan Inc

Compounds as tyrosine kinase modulators

The present invention is directed to novel compounds of formula i. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.. ... Allergan Inc

Enhanced bimatoprost ophthalmic solution

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.. ... Allergan Inc

Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use

Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.. ... Allergan Inc

Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions

The present invention relates to method for treating skin diseases and skin conditions in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.. . ... Allergan Inc

(-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

The present invention is directed to (−)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, a pharmaceutical composition comprising said salt, a process for making said salt, and the use of said salt in the treatment of pain.. . ... Allergan Inc

2,5-dioxoimidazolidin-1-yl-3-urea derivatives as formyl peptide modulators

The present invention relates to 1-(2,5-dioxoimidazolidin-1-y)-3-substituted urea compounds, processes for preparing them, pharmaceutical compositions containing them, their use as pharmaceuticals as modulators of the fpr2 receptor, and to methods of treating inflammatory diseases or conditions in a subject in need thereof by administering the compound(s) or pharmaceutical composition to the subject.. . ... Allergan Inc

Sustained release bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction.. . ... Allergan Inc

Hyaluronic acid formulation containing pyruvate

Pyruvate may be used to stabilize hyaluronic acid compositions. For example, these compositions may have improved heat and/or storage stability.. ... Allergan Inc

Urea hydantoin derivatives as formyl peptide modulators

The present invention relates to urea hydantoin compounds, processes for preparing them, pharmaceutical compositions containing them, and their use as pharmaceuticals as modulators of the fpr2 receptor, and to methods of treating inflammatory diseases or conditions in a subject in need thereof by administering the compound(s) or pharmaceutical composition to the subject.. . ... Allergan Inc

Hypotensive lipid-containing biodegradable intraocular implants and related methods

Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

Soft filled prosthesis shell with discrete fixation surfaces

A soft prosthetic implant shell, such as a silicone breast implant shell, that has discrete fixation surfaces thereon for tissue adhesion. The fixation surfaces may be provided on the posterior face of the shell, as well as either on the periphery or at discrete areas on the anterior face. ... Allergan Inc

Methods of intracellular conversion of single-chain proteins into their di-chain form

The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.. . ... Allergan Inc

11/03/16 / #20160317571

Injectable monophase hydrogels

An injectable monophase hydrogel is provided and is made of a reaction mixture of a high molecular weight hyaluronic acid and a low molecular weight hyaluronic acid.. . ... Allergan Inc

11/03/16 / #20160317550

Methods for fat reduction

Disclosed herein are methods, compounds, and compositions for fat reduction, and in particular fat reduction without significant hair growth and/or additional hair growth.. . ... Allergan Inc

11/03/16 / #20160317284

Self-sealing shell for inflatable prostheses

A self-sealing shell useful as a component of a soft fluid-filled prosthetic implant is provided. The shell is at least partly constructed of a wall made of a colloid of an elastomeric polymer matrix and particles of a water-swellable material distributed therein.. ... Allergan Inc

10/27/16 / #20160310635

Dermal filler compositions for fine line treatment

The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.. . ... Allergan Inc

10/27/16 / #20160310505

Prostamides for enhancement of leptin production

Prostamides such as bimatoprost and its pro-drugs for enhancement of leptin production and appetite suppression.. . ... Allergan Inc

10/27/16 / #20160310466

Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism

The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. ... Allergan Inc

10/27/16 / #20160310416

Compositions containing alpha-2-adrenergic agonist components

Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. ... Allergan Inc

10/20/16 / #20160303185

Methods and devices for desmopressin drug delivery

Disclosed are devices for urine voiding postponement, and methods for treating conditions such as central diabetes insipidus, enuresis, nocturia, urinary frequency or incontinence. The devices deliver a desmopressin flux through the skin of a patient in a low dose amount just necessary to achieve a desired anti-diuretic effect without undesirable side effects such as hyponatremia. ... Allergan Inc

10/20/16 / #20160303119

Combination of brimonidine and timolol for topical ophthalmic use

Disclosed are pharmaceutical compositions comprising brimonidine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.. . ... Allergan Inc

10/20/16 / #20160303083

Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3himidazole derivatives for treating retinal diseases

The present invention relates to pharmaceutical compositions, containing 4-[1-(2,3-dimethylphenyl)ethyl]-1h-imidazole, (s) 4 [1-(2,3-dimethylphenyl)ethyl]-1h-imidazole or (s) [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, their use as pharmaceuticals for the treatment of retinal diseases, for retinal neuroprotection and vision enhancement.. . ... Allergan Inc

10/06/16 / #20160289271

Cyclosporins modified on the mebmt sidechain by heterocyclic rings

The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.. . ... Allergan Inc

09/29/16 / #20160279401

Dissolvable microneedles for skin treatment

A skin treatment device is provided including bioerodible polymeric microneedles which are designed to more effectively deliver beneficial agents to the skin. The device includes a flexible substrate and an arrangement, for example, an array, of microneedles projecting from the substrate.. ... Allergan Inc

09/29/16 / #20160279296

Hyaluronic acid-based gels including lidocaine

Disclosed herein are soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. ... Allergan Inc

09/29/16 / #20160279290

Dermal filler compositions including antioxidants

Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin c derivatives. The compositions provide for extended release of active vitamin c into tissue, promoting collagenesis and other benefits to skin.. ... Allergan Inc

09/29/16 / #20160279143

Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide f2 alpha agonists

The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.. ... Allergan Inc

09/22/16 / #20160272681

Cyclosporin a form 2 and method of making same

Disclosed herein are methods of making cyclosporin a form 2.. . ... Allergan Inc

09/22/16 / #20160272581

Phenylcarbamate derivatives as formyl peptide receptor modulators

The present invention relates to n-phenyl carbamate derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide 2 receptor.. . ... Allergan Inc

09/22/16 / #20160271207

Autoclavable suspensions of cyclosporin a form 2

Disclosed herein are autoclavable formulations of cyclosporin a form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.. . ... Allergan Inc

09/15/16 / #20160263202

Injection paradigm for administration of botulinum toxins

Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.. ... Allergan Inc

09/08/16 / #20160256424

Ophthalmic compositions and methods for treating eyes

Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.. . ... Allergan Inc

09/08/16 / #20160256382

Sustained-release reservoir implants for intracameral drug delivery

The present invention provides a sustained release implant for intraocular use to treat elevated intraocular pressure, which implant is configured for intracameral or anterior vitreal administration to a patient with elevated intraocular pressure (iop), said implant comprising a core of an antihypertensive agent surrounded by a polymer, which limits the rate of passage of the antihypertensive agent from the implant into the eye of said patient and said implant provides a linear rate of release of therapeutically effective amounts of said anti-hypertensive agent into the eye for a period of time of between 14 days and 365 days.. . ... Allergan Inc

08/25/16 / #20160243131

Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods

. . Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

08/25/16 / #20160243079

Ketorolac tromethamine compositions for treating or preventing ocular pain

Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.. ... Allergan Inc

08/25/16 / #20160243078

Ketorolac tromethamine compositions for treating or preventing ocular pain

The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution which provides increased visual acuity in users and wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient which is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.. . ... Allergan Inc

08/25/16 / #20160243065

Topical dapsone and dapsone/adaplene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

08/25/16 / #20160243032

Steroid-containing sustained release intraocular implants and related methods

Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. ... Allergan Inc

08/18/16 / #20160235780

Eye drop formulation with enhanced properties by combining sodium hyaluronate with carboxymethylcellulose

Embodiments described herein relate to formulations for and methods of use for eye drop formulations comprising carboxymethyl cellulose (cmc) and hyaluronic acid (ha) with an improved distribution on the cornea during blinking.. . ... Allergan Inc

08/18/16 / #20160235711

Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

The present invention relates to novel amide derivatives of n-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the n-formyl peptide receptor like-1 (fprl-1) receptor.. . ... Allergan Inc

08/18/16 / #20160235666

Two part formulation system for ophthalmic delivery

Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. ... Allergan Inc

08/11/16 / #20160228407

Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators

The present invention relates to novel bis-sulfonamide derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.. . ... Allergan Inc

08/11/16 / #20160228359

Ophthalmic compositions and methods for treating ophthalmic conditions

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. ... Allergan Inc

08/11/16 / #20160228345

Compositions and methods for hair growth

The present invention is directed to compositions and methods comprising the use of bimatoprost and cyclosporine, used concurrently and in combination, to grow hair and for the treatment of all types of hair loss conditions such as but not limited toalopecia areata. The present invention is also directed to compositions containing bimatoprost and cyclosporine a to grow hair on the scalp and other areas of the body and methods of administration of the compositions.. ... Allergan Inc

08/04/16 / #20160220729

Heat stable hyaluronic acid compositions for dermatological use

The disclosure provides hyaluronic acid (ha) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. ... Allergan Inc

08/04/16 / #20160220677

Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

The present invention is based on the discovery that a marked increase in aqueous stability (and thereby shelf life) of prostanoid agonist prodrug compositions is achieved by incorporating into the compositions certain well-defined carboxylic acids, and thereafter adjusting the ph of the compositions from about 4.0 to about 8.0. As a result, the compositions and methods of the invention provide the aqueous stability required for marketable topical drug treatments of a wide variety of ocular disorders.. ... Allergan Inc

07/28/16 / #20160213854

Mechanical syringe accessory

Described herein are syringe accessories that can be attached to standard syringes. These accessories utilize one or more mechanisms that can provide at least one additional sensory feedback to the user when performing an aliquot or dosed injection. ... Allergan Inc

07/28/16 / #20160213813

Threads of cross-linked hyaluronic acid and methods of uses thereof

This invention relates generally to threads of hyaluronic acid, methods of making such threads and uses thereof, for example, in aesthetic applications (e.g., facial contouring, dermal fillers), surgery (e.g., sutures), drug delivery, negative pressure wound therapy, moist wound dressing, and the like.. . ... Allergan Inc

07/28/16 / #20160213457

Prosthetic device and method of manufacturing the same

A biocompatible surgical silk mesh prosthetic device employs a knit pattern that substantially prevents unraveling and preserves the stability of the mesh device, especially when the mesh device is cut. An example prosthetic device employs a knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes. ... Allergan Inc

07/28/16 / #20160213456

Silk medical device

An implantable knitted silk mesh for use in human soft tissue support and repair having a particular knit pattern that substantially prevents unraveling and preserves the stability of the mesh when cut, the knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes.. . ... Allergan Inc

07/14/16 / #20160201046

Degradable clostridial toxins

. . . . The specification discloses clostridial toxins or clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.. . ... Allergan Inc

07/14/16 / #20160200767

Cyclosporin derivatives wherein the mebmt sidechain has been cyclized

The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin d and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (i/r) injury, including myocardial fr injury, cerebral i/r injury, and ocular or retinal i/r injury.. . ... Allergan Inc

07/14/16 / #20160199428

Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.. . ... Allergan Inc

07/14/16 / #20160199387

Prostamide-containing intraocular implant

Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.. . ... Allergan Inc

07/14/16 / #20160199297

Biodegradable intravitreal tyrosine kinase implants

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. ... Allergan Inc

07/07/16 / #20160194311

Substituted nicotinamide derivatives as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

07/07/16 / #20160193230

Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor

Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.. . ... Allergan Inc

07/07/16 / #20160193026

Pliable silk medical device

An implantable, pliable knitted silk mesh for use in human soft tissue support and repair having a particular knit pattern that substantially prevents unraveling and preserves the stability of the mesh when cut, the knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes.. . ... Allergan Inc

06/16/16 / #20160166707

Stabilization of therapeutic agents to facilitate administration

The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated c. ... Allergan Inc

06/09/16 / #20160158446

Syringe assembly

An insert useful with a dermal filler syringe is provided for facilitating mixing of active agents with dermal fillers being injected into skin.. . ... Allergan Inc

06/09/16 / #20160158249

Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an glucocorticoid derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.. ... Allergan Inc

06/09/16 / #20160158199

Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists

Disclosed herein is a method of upregulating regulatory t-cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.. . ... Allergan Inc

06/02/16 / #20160151542

Porogen compositions, methods of making and uses

The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.. . ... Allergan Inc

06/02/16 / #20160151468

Suture line administration technique using botulinum toxins

The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull.. ... Allergan Inc

06/02/16 / #20160151349

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

06/02/16 / #20160151241

High recovery vial adaptor

Some medicaments, such as botulinum toxin, are sold in small glass vials with a cap that comprises a seal. The seal is punctured to allow liquid to be added to reconstitute the medicament, then allow the medicament to be withdrawn through a needle into a syringe. ... Allergan Inc

05/26/16 / #20160144302

Fat processing system

Methods and devices for treating lipoaspirate for use in fat grafting procedures are provided and generally include a canister for containing lipoaspirate, a separation mechanism structured to separate both oils and other materials from cellular components of lipoaspirate contained in the canister. The separation mechanism includes filters having different filtering capacities, for example, different pore sizes.. ... Allergan Inc

05/26/16 / #20160144125

Syringe extrusion accessory

Described herein are syringe extrusion accessories comprising: a handle operatively coupled to an attachment portion configured to attach to a syringe; and at least one pawl operatively coupled to the handle and configured to engage with a plunger of the syringe, wherein the syringe extrusion accessory is configured to transfer a substantially perpendicular force applied to the handle to an axial force to push the plunger and extrude a product from the syringe.. . ... Allergan Inc

05/26/16 / #20160143988

Methods of providing therapeutic effects using cyclosporin components

Methods of treating an eye of a human or animal include administering to an eye of a human or animal a composition in the form of an emulsion including water, a hydrophobic component and a cyclosporin component in a therapeutically effective amount of less than 0.1% by weight of the composition. The weight ratio of the cyclosporin component to the hydrophobic component is less than 0.8.. ... Allergan Inc

05/26/16 / #20160143977

Stabilized omega-3 ophthalmic compositions

Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.. . ... Allergan Inc

05/19/16 / #20160137616

Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors' modulators

The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.. . ... Allergan Inc

05/12/16 / #20160129074

Suspensions of cyclosporin a form 2

Disclosed herein are methods of formulating cyclosporin a form 2.. . ... Allergan Inc

05/05/16 / #20160120821

Drug eluting silicone gel sheeting for wound healing and scar reduction

Provided are methods of making devices that can be applied to the skin to promote healing of wounds and the reduction or prevention of scarring. The devices include compositions of various silicone compounds loaded with active pharmaceutical agents.. ... Allergan Inc

05/05/16 / #20160120784

Method for improving duration of effect of dermal filler treatment

A method of treating midface volume deficit in a person is provided. The method generally includes administering a dermal filler, such as a hyaluronic acid based dermal filler, in a sequence of injections that enhance effectiveness and/or duration of the filler. ... Allergan Inc

04/28/16 / #20160114101

Injection device and method for diluting an injectable fluid

An injection device enables a user to control the dilution ratio of mixed injectable fluid. In one embodiment, the injection device includes a drive unit configured to apply extrusion forces to fluids. ... Allergan Inc

04/28/16 / #20160113934

Preservative free bimatoprost and timolol solutions

The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.. . ... Allergan Inc

04/07/16 / #20160097045

Process and system for obtaining botulinum neurotoxin

. . . . Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.. . ... Allergan Inc

04/07/16 / #20160096837

Substituted 1,2,3,4-tetrahydropyrido[3,4-e] pyrrolo[1,2-a]pyrimidines as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

04/07/16 / #20160096832

Kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. . ... Allergan Inc

04/07/16 / #20160095984

Devices for injection and dosing

Injection devices are provided which include a handpiece capable of housing a cartridge containing an injectable composition, and a head coupled to the handpiece and housing a plurality of retractable needles and a dosing mechanism. Methods of treating skin surfaces are also provided.. ... Allergan Inc

04/07/16 / #20160095695

Silk fibroin hydrogels and uses thereof

The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such molecules, methods of making fibroin hydrogels, fibroin hydrogels and fibroin hydrogel formulations useful for a variety of medical uses, including, without limitation uses as bulking agents, tissue space fillers, templates for tissue reconstruction or regeneration, cell culture scaffolds for tissue engineering and for disease models, surface coating to improve medical device function, or drug delivery devices.. . ... Allergan Inc

03/31/16 / #20160090372

Compounds as tyrosine kinase modulators

The present invention is directed to novel compounds of formula i. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.. ... Allergan Inc

03/31/16 / #20160089475

Hyaluronic acid-collagen matrices for dermal filling and volumizing applications

Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.. ... Allergan Inc

03/24/16 / #20160083432

Crystalline form of cyclosporin a, methods of preparation, and methods for use thereof

. . The present invention relates generally to crystalline forms of cyclosporin a and particularly to a newly identified form of cyclosporin a. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.. ... Allergan Inc

03/24/16 / #20160083342

Sulfur derivatives as chemokine receptor modulators

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.. . ... Allergan Inc

03/24/16 / #20160082150

Hyaluronic acid gels crosslinked by sodium trimetaphosphate

Injectable dermal fillers including hyaluronic acid crosslinked with trimetaphosphate, and methods of making same are provided.. . ... Allergan Inc

03/24/16 / #20160082007

Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. ... Allergan Inc

03/24/16 / #20160081898

Compositions for enhancing nail health

The present invention is directed to compositions and methods for enhancing the health of nails and cuticles in a mammal, including humans. The compositions may be administered topically to the nail bed, nail matrix and cuticle in an amount effective to enhance nail health. ... Allergan Inc

03/17/16 / #20160074485

Methods for treating osteoarthritis pain

Methods for alleviating osteoarthritis-associated symptoms by selecting a treatment-eligible patient and local administration of a clostridial derivative, such as a botulinum toxin, to an osteoarthritis-affected site are disclosed herein.. . ... Allergan Inc

03/17/16 / #20160074418

Ocular implant made by a double extrusion proces

The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end plga, and deliver active agents into an ocular region without a high burst release.. ... Allergan Inc

03/17/16 / #20160074307

Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof

The present invention provides threads of hyaluronic acid, and/or derivatives thereof, methods of making thereof and uses thereof, for example, in aesthetic applications (e.g., dermal fillers), surgery (sutures), drug delivery, etc.. . ... Allergan Inc

03/17/16 / #20160074152

Inflatable prostheses and methods of making same

A laminate useful as a component of a medical implant, for example, useful as a component of an inflatable tissue expander. The laminate includes a base layer, an intermediate layer, and a top layer. ... Allergan Inc

03/10/16 / #20160067319

Method for treating premature ejaculation with a botulinum neurotoxin

. . . . Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a clostridial neurotoxin, such a botulinum neurotoxin, to the patient, are provided.. . ... Allergan Inc

03/10/16 / #20160067222

Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl]methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals.. . ... Allergan Inc

03/03/16 / #20160058816

Methods for treating scars and aging skin

Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include bulbine frutescens, centella asiatica and a phenol derived from olives, such as oleuropein. ... Allergan Inc

03/03/16 / #20160058693

Methods for treating scars and aging skin

Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include bulbine frutescens, centella asiatica and a phenol derived from olives, such as oleuropein. ... Allergan Inc

02/25/16 / #20160051534

Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8- tetrahydro-quinoline for treating skin diseases and conditions

The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof.. . ... Allergan Inc

02/25/16 / #20160051499

Comparative efficacy and tolerability of dapsone 5% in adult versus adolescent females with acne vulgaris

The present invention provides a method of treating facial acne vulgaris in an adult female (≧18 years of age) in need of such treatment, comprising topically administering dapsone 5% gel twice daily to the face of the adult female.. . ... Allergan Inc

02/18/16 / #20160045489

N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors

The present invention relates to novel n-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.. . ... Allergan Inc

02/18/16 / #20160045413

Methods for making compositions for improving skin conditions

The present specification discloses fluid compositions comprising a matrix polymer and stabilizing component, methods of making such fluid compositions, and methods of treating skin conditions in an individual using such fluid compositions.. . ... Allergan Inc

02/11/16 / #20160039880

Cyclosporin a analogs

The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.. . ... Allergan Inc

02/11/16 / #20160039819

Muscarinic agonists

Compounds of formula (i) and methods are provided for the treatment of disease or conditions in which modification of cholinergic, especially muscarinic receptor activity, has a beneficial effect.. . ... Allergan Inc

02/11/16 / #20160038654

Sustained release intraocular implants and methods for treating ocular vasculopathies

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

02/11/16 / #20160038466

Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol

Disclosed herein is a pharmaceutical composition comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol and methods of using the composition to treat chronic pain.. . ... Allergan Inc

02/11/16 / #20160038396

Dermal filler

Improved dermal filler formulation comprising a hyaluronic acid and a botulinum toxin.. . ... Allergan Inc

02/11/16 / #20160038269

Prosthetic fabric structure

Disclosed herein is an implantable prosthesis for breast augmentation or reconstruction procedures. The prosthesis comprises a biocompatible and biodegradable fabric structure comprising one or more individual yarns comprised of sericin-extracted native fibroin fibers, wherein the yarns are intertwined to produce the fabric structure. ... Allergan Inc

02/04/16 / #20160030580

Topical dapsone and dapsone/adaplene compositions and methods for use thereof

Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. ... Allergan Inc

02/04/16 / #20160030570

Formulations of biologics for intravesical instillation

Pharmaceutical formulations comprising a clostridial derivative and a permeabilizing agent for intravesical instillation are disclosed.. . ... Allergan Inc

02/04/16 / #20160030334

Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

01/28/16 / #20160022866

Porous materials, methods of making and uses

. . The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.. . ... Allergan Inc

01/28/16 / #20160022765

Cyclosporin analogs

Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.. . ... Allergan Inc

01/28/16 / #20160022581

Processes for making cyclic lipid implants for intraocular use

Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.. ... Allergan Inc

01/21/16 / #20160015718

Oil-in-water method for making polymeric implants containing a hypotensive lipid

Biocompatible microparticles include an ophthalmically active cyclic lipid component and a biodegradable polymer that is effective, when placed into the subconjunctival space, in facilitating release of the cyclic lipid component into the anterior and posterior segments of an eye for an extended period of time. The cyclic lipid component can be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

01/21/16 / #20160015717

Enhanced bimatoprost ophthalmic solution

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.. ... Allergan Inc

01/21/16 / #20160015632

Suspension compositions of cyclosporin a for subconjunctival and periocular injection

The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin a and in some embodiments, form 1 or form 2 cyclosporin a. ... Allergan Inc

01/14/16 / #20160008441

Methods for treatment of incontinence associated with sexual activity

The invention provides compositions and methods for treating incontinence associated with sexual activity.. . ... Allergan Inc

01/14/16 / #20160008354

Sustained release intraocular implants and methods for preventing retinal dysfunction

Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. ... Allergan Inc

01/07/16 / #20160003824

Method of detecting cleaved snap25 in tissue samples

Methods and compositions for detecting bont/a enzymatic activity in tissues or a tissue sample are described herein. The invention encompasses antibodies that bind preferentially to bont/a cleaved snap25 and is able to preferentially detect bont/a cleaved snap25, as compared to intact (non-cleaved) snap25, in a tissue sample.. ... Allergan Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Allergan Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Allergan Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###